STOCK TITAN

Kamada (KMDA) CEO Amir London details shares and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Kamada Ltd Chief Executive Officer Amir London reported his equity holdings in the company. He directly owns 61,875 Ordinary Shares and also holds several grants of options to purchase Ordinary Shares, each covering 100,000 underlying shares at exercise prices of $6.15 and $7.55 per share, with expirations in 2029 and 2035. The options are exercisable using a net-exercise method, meaning only the in-the-money value is settled in shares rather than paying cash for the full exercise price.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
London Amir

(Last) (First) (Middle)
15D YEKUTIEL ADAM ST.

(Street)
KFAR SABA L3 44282

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026
3. Issuer Name and Ticker or Trading Symbol
KAMADA LTD [ KMDA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 61,875 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase Ordinary Shares(1) 12/22/2023 06/22/2029 Ordinary Shares 100,000 $6.15(2) D
Options to purchase Ordinary Shares(1) 12/22/2024 06/22/2029 Ordinary Shares 100,000 $6.15(2) D
Options to purchase Ordinary Shares(1) 12/22/2025 06/22/2029 Ordinary Shares 100,000 $6.15(2) D
Options to purchase Ordinary Shares(1) 12/10/2026 12/10/2035 Ordinary Shares 100,000 $7.55(2) D
Options to purchase Ordinary Shares(1) 12/22/2026 06/22/2029 Ordinary Shares 100,000 $6.15(2) D
Options to purchase Ordinary Shares(1) 12/10/2027 12/10/2035 Ordinary Shares 100,000 $7.55(2) D
Options to purchase Ordinary Shares(1) 12/10/2028 12/10/2035 Ordinary Shares 100,000 $7.55(2) D
Options to purchase Ordinary Shares(1) 12/10/2029 12/10/2035 Ordinary Shares 100,000 $7.55(2) D
Explanation of Responses:
1. These options to purchase ordinary shares are exercisable using a net-exercise method
2. All exercise prices presented in U.S. dollars represent a convenience translation from NIS based on the representative exchange rate of the Bank of Israel as of March 13, 2026.
/s/ Amir London 03/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider holdings did Kamada (KMDA) report for CEO Amir London?

Kamada’s CEO Amir London disclosed direct ownership of 61,875 Ordinary Shares. He also holds multiple option grants to purchase Kamada Ordinary Shares, each for 100,000 underlying shares, providing additional potential equity exposure if the options are exercised in the future.

What are the exercise prices of Amir London’s Kamada (KMDA) stock options?

Amir London’s disclosed options have exercise prices of $6.15 and $7.55 per Ordinary Share. These prices represent the cost basis at which he can acquire Kamada shares through option exercise, subject to the terms and vesting of each grant.

When do Amir London’s Kamada (KMDA) options expire?

The reported options held by Amir London expire on June 22, 2029 and December 10, 2035, depending on the specific grant. These expiration dates define how long he has the right to exercise the options and potentially convert them into Ordinary Shares.

How are Amir London’s Kamada (KMDA) options exercisable under the filing?

The options are exercisable using a net-exercise method. Instead of paying the full cash exercise price, only the in-the-money value is settled in shares, which generally reduces the cash needed and issues fewer shares than a full cash exercise would.

Does the Kamada (KMDA) CEO Form 3 show any recent share purchases or sales?

The disclosure lists holdings of Ordinary Shares and options but shows no buy or sell transactions. It functions as an initial statement of equity positions rather than reporting new open-market purchases, sales, or option exercises by the CEO.

What type of security does Amir London directly own in Kamada (KMDA)?

Amir London directly owns Ordinary Shares of Kamada, totaling 61,875 shares. In addition, he holds options whose underlying security is also Kamada Ordinary Shares, giving him the right, but not the obligation, to acquire more shares at preset exercise prices.
Kamada Ltd

NASDAQ:KMDA

View KMDA Stock Overview

KMDA Rankings

KMDA Latest News

KMDA Latest SEC Filings

KMDA Stock Data

501.83M
31.45M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Israel
Rehovot